1. Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials

   • Maria Ormhøj
   • Hinrich Abken
   • Sine R. Hadrup

   Review Article Open access 23 February 2022 Pages: 2301 - 2311

   

2. The nuclear transportation of PD-L1 and the function in tumor immunity and progression

   • Liyan Qu
   • Jiakang Jin
   • Wei Yu

   Review Article 05 March 2022 Pages: 2313 - 2323

   

3. CMTM6 as a master regulator of PD-L1

   • Mahmoud Mohammad Yaseen
   • Nizar Mohammad Abuharfeil
   • Homa Darmani

   Review Article 16 March 2022 Pages: 2325 - 2340

   

4. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma

   • Peng Song
   • Wenbin Li
   • Jie He

   Original Article 13 February 2022 Pages: 2341 - 2354

   

5. VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients

   • ANM Nazmul H. Khan
   • Tiffany R. Emmons
   • Brahm H. Segal

   Original Article 15 February 2022 Pages: 2355 - 2369

   

6. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers

   • Yulong Zheng
   • Anna Rachelle Austria Mislang
   • Nong Xu

   Original Article 15 February 2022 Pages: 2371 - 2379

   

7. Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood

   • Corinna U. Keber
   • Marcus Derigs
   • Jörg Hänze

   Original Article Open access 20 February 2022 Pages: 2381 - 2389

   

8. Transient 40 °C-shock potentiates cytotoxic responses of Vδ2⁺ γδ T cell via HSP70 upregulation

   • Li Lin
   • Yan Chen
   • Yangzhe Wu

   Original Article 23 February 2022 Pages: 2391 - 2404

   

9. Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors

   • Fyza Y. Shaikh
   • Joell J. Gills
   • Cynthia L. Sears

   Original Article 26 February 2022 Pages: 2405 - 2420

   

10. Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy

    • Yosuke Sato
    • Cierra N. Casson
    • Michael H. Shaw

    Original Article Open access 03 March 2022 Pages: 2421 - 2431

    

11. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma

    • Guidong Zhu
    • Junwen Zhang
    • Fusheng Liu

    Original Article 06 March 2022 Pages: 2433 - 2448

    

12. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma

    • Li-Hua Qu
    • Qian Fang
    • Hui-Fen Dong

    Original Article 07 March 2022 Pages: 2449 - 2467

    

13. Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients

    • Iwona Kwiecień
    • Elżbieta Rutkowska
    • Joanna Domagała-Kulawik

    Original Article 07 March 2022 Pages: 2469 - 2483

    

14. Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial

    • David M. Loeb
    • Ji Won Lee
    • Hyoung Jin Kang

    Original Article Open access 09 March 2022 Pages: 2485 - 2495

    

15. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells

    • Jutatip Panaampon
    • Ryusho Kariya
    • Seiji Okada

    Original Article 09 March 2022 Pages: 2497 - 2509

    

16. Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer

    • Hongyu Zhang
    • Zilong Liu
    • Di Ge

    Original Article 12 March 2022 Pages: 2511 - 2522

    

17. Tumour cell-activated platelets modulate the immunological activity of CD4⁺, CD8⁺, and NK cells, which is efficiently antagonized by heparin

    • Lukas M. Gockel
    • Katrin Nekipelov
    • Martin Schlesinger

    Original Article Open access 14 March 2022 Pages: 2523 - 2533

    

18. Immune epitopes identification and designing of a multi-epitope vaccine against bovine leukemia virus: a molecular dynamics and immune simulation approaches

    • Abdus Samad
    • Nigar Sultana Meghla
    • Md. Shahedur Rahman

    Original Article 16 March 2022 Pages: 2535 - 2548

    

19. Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer

    • Marion Thibaudin
    • Emeric Limagne
    • Francois Ghiringhelli

    Original Article 16 March 2022 Pages: 2549 - 2563

    

20. Parvimonas micra is associated with tumour immune profiles in molecular subtypes of colorectal cancer

    • Thyra Löwenmark
    • Xingru Li
    • Richard Palmqvist

    Original Article Open access 17 March 2022 Pages: 2565 - 2575

    

21. Correction to: Functional virus‑specific memory T cells survey glioblastoma

    • Jianfang Ning
    • Noah V. Gavil
    • Pamela C. Rosato

    Correction 18 February 2022 Pages: 2577 - 2579

    

22. Correction to: Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden

    • Julia Femel
    • Luuk van Hooren
    • Anna-Karin Olsson

    Correction Open access 28 February 2022 Pages: 2581 - 2581